A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~20 mi. (Mexico City, Mexico, +192 more cities)

Grupo Medico Camino Sc

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

~20 mi. (Mexico City, Mexico, +247 more cities)

Local Institution

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

~20 mi. (Mexico City, Mexico, +235 more cities)

Instituto Nacional De Cancerologia de Mexico

Prostate Adenocarcinoma

abiraterone, +9 more drugs

hormone therapy, +2 more types

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~20 mi. (Mexico City, Mexico, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

~20 mi. (Mexico City, Mexico, +180 more cities)

Exelixis Clinical Site #187

Prostate Adenocarcinoma

atezolizumab, +1 more drug

immunotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~20 mi. (Mexico City, Mexico, +184 more cities)

Health Pharma Professional Research S.A. de C.V:

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

~20 mi. (Mexico City, Mexico, +88 more cities)

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

FGFR2 Fusion

Intrahepatic Cholangiocarcinoma

futibatinib

targeted therapy

Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants

~20 mi. (Mexico City, Mexico, +71 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

cobolimab, +2 more drugs

chemotherapy, +1 more type

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

~20 mi. (Mexico City, Mexico, +49 more cities)

Local Institution

Clear Cell Renal Cell Carcinoma

axitinib, +3 more drugs

immunotherapy, +2 more types

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

~20 mi. (Mexico City, Mexico, +12 more cities)

Local Institution

Head and Neck Squamous Cell Carcinoma, +2 more conditions

BMS-986315, +2 more drugs

immunotherapy, +1 more type

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

~21 mi. (Cuauhtémoc, Mexico, +163 more cities)

Investigational Site Number :4840003

CEACAM5 Expression

Non-Squamous Non-Small Cell Lung Carcinoma

tusamitamab ravtansine

chemotherapy, +1 more type

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

~24 mi. (México, Mexico, +202 more cities)

Site MX52002

CLDN18 Expression, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

modified FOLFOX6 regimen, +1 more drug

chemotherapy, +1 more type